Therapeutic potential of vasopressin receptor antagonists

Drugs

Volumn 67, Issue 6, 2007, Pages 847-858

  Ali, Farhan ^a   Guglin, Maya ^a   Vaitkevicius, Peter ^a   Ghali, Jalal K ^a,b  

^a WAYNE STATE UNIVERSITY   (United States)

^b DETROIT RECEIVING HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ALCOHOL; ALDOSTERONE ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ARGIPRESSIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; CONIVAPTAN; DEMECLOCYCLINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; LIXIVAPTAN; N TERT BUTYL 4 [5' ETHOXY 4 (2 MORPHOLINOETHOXY) 2' OXOSPIRO[CYCLOHEXANE 1,3' INDOLE] 1' SULFONYL] 3 METHOXYBENZAMIDE; OPC 1061; OPIATE DERIVATIVE; PHENYTOIN; PLACEBO; RELCOVAPTAN; SATAVAPTAN; SODIUM CHLORIDE; TOLVAPTAN; UNCLASSIFIED DRUG; VASOPRESSIN; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V1B RECEPTOR; VASOPRESSIN V2 RECEPTOR;

ABSENCE OF SIDE EFFECTS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DILATATION; DEHYDRATION; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG URINE LEVEL; ELECTROLYTE DISTURBANCE; HEART AFTERLOAD; HEART FAILURE; HEART HYPERTROPHY; HEART MUSCLE; HUMAN; HYPERTENSION; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; LIVER CIRRHOSIS; LOADING DRUG DOSE; MONOTHERAPY; NEPHROGENIC DIABETES INSIPIDUS; NONHUMAN; POLYURIA; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SERUM OSMOLALITY; SIDE EFFECT; THIRST; UNSPECIFIED SIDE EFFECT; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; XEROSTOMIA;

EID: 34247259624     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767060-00002     Document Type: Review

References (67)

1. Guyton AC. The body fluids and kidneys. In: Guyton AC, Hall JE, editors. Textbook of medical physiology. Philadelphia (PA): WB Saunders Company, 2006: 291-414
2. Burrell LM, Risvanis J, Johnston CI, et al. Vasopressin receptor antagonism: a therapeutic option in heart failure and hypertension. Exp Physiol 2000; 85: 259S-65S
3. Hupf H, Grimm D, Riegger GAJ, et al. Evidence for a vasopressin system in the rat heart. Circ Res 1999; 84: 365-70
4. Brooks VL, Keil LC, Reid IA. Role of the renin-angiotensin system in the control of vasopressin secretion in conscious dogs. Circ Res 1986; 58: 829-38
5. Verbalis JG. Vasopressin V2 receptor antagonists. J Mol Endocrinol 2002; 29: 1-9
6. Tahara A, Tomura Y, Wada K, et al. Effects of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte. Cardiovasc Res 1998; 38: 198-205
7. Fukuzawa J, Haneda T, Kikuchi K. Arginine vasopressin increases the rate of protein synthesis in isolated perfused adult rat heart via the V1 receptor. Mol Cell Biochem 1999; 195: 93-8
8. Nakamura Y, Haneda T, Osakie J, et al. Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V, a receptor. Eur J Pharmacol 2000; 39: 39-48
9. Nielsen S, Kwon TH, Christensen BM, et al. Physiology and pathophysiology of renal aquaporins. J Am Soc Nephrol 1999; 10: 647-63
10. Sonnenburg WK, Smith WL. Regulation of cyclic AMP metabolism in rabbit cortical collecting tubule cells by prostaglandins. J Biol Chem 1988; 263: 6155-60
11. Bernat A, Hoffmann P, Dumas A, et al. V2 receptor antagonism of DDAVP-induced release of hemostasis factors in conscious dogs. J Pharmacol Exp Ther 1997; 282: 597-602
12. Lolait SJ, O'Carroll AM, Mahan LC, et al. Extrapituitary expression of the rat V1b vasopressin receptor gene. Proc Natl Acad Sci USA 1995; 92: 6783-7
13. Rouleau J-L, Packer M, Moye L, et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol 1994; 24: 583-91
14. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990; 82: 1724-9
15. Goldsmih SR, Francis GS, Cowley AW, et al. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol 1983; 1: 1385-90
16. Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med 2000; 342: 1581-9
17. Palmer BF, Gates JR, Lader M. Causes and management of hyponatremia. Ann Pharmacother 2003; 37: 1694-702
18. Upadhyay A, Jaber B, Madias N. Incidence and prevalence of hyponatremia. Am J Med 2006; 119: S30-5
19. Lee DS, Austin PC, Rouleau JL, et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 2003; 40: 1801-7
20. Barter FC, Schwartz WB. The syndrome of inappropriate secretion of antidiuretic hormone. Am J Med 1967; 42: 790-806
21. Bichet D, Szatalowicz V, Chaimovitz C, et al. Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann Intern Med 1982; 96: 413-7
22. Schrier RW, Ecder T. Unifying hypothesis of body fluid volume regulation: implications for cardiac failure and cirrhosis. Mt Sinai J Med 2001; 68: 350-61
23. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med 1999; 341: 577-85
24. Domanski M, Tian X, Haigney M, et al. Diuretic use, progressive heart failure, and death in patients in the DIG study. J Cardiac Failure 2006; 12 (5): 327-32
25. Domanski M, Norman J, Pitt B, et al. Diuretic use, progressive heart failure and death in patients in the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 2003; 42: 705-8
26. Cooper HA, Dries DL, Davis CE, et al. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 1999; 100: 1311-5
27. Greenberg A, Verbalis JG. Vasopressin receptor antagonists. Kidney Int 2006; 69: 2124-1
28. Zerbe R, Stropes L, Robertson G. Vasopressin function in the syndrome of inappropriate antidiuresis. Ann Rev Med 1980; 31: 315-27
29. Fujiwara TM, Bichet DG. Molecular biology of hereditary diabetes insipisus. J Am Soc Nephrol 2005; 16: 2836-46
30. Bernier V, Morello JP, Zarruk A, et al. Pharmacologic chaperones as a potential treatment for x-linked nephrogenic diabetes insipidus. J Am Soc Nephrol 2006; 17: 232-43
31. Holmes CL, Landry DW, Granton JT. Science review: vasopressin and the cardiovascular system, part 1: receptor physiology. Crit Care 2003; 7 (6): 427-34
32. Dunser MW, Mayr AL, Ulmer H, et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation 2003; 107 (18): 2313-9
33. Lindner KH, Dirks B, Strohmenger HU, et al. Randomized comparison of epinephrine and vasopressin in patients with out-of-hospital ventricular fibrillation. Lancet 1997 Feb 22; 349 (9051): 535-7
34. Gavras I, Gavras H. Role of vasopressin in hypertensive disorders. In: Laragh JH, Brenner BM, editors. Hypertension: pathophysiology, diagnosis, and management. 2nd ed. New York: Raven Press Ltd, 1995
35. Ribiero A, Mulinasi R, Gavras I, et al. Sequential elmination of pressor mechanisms in severe hypertention in humans. Hypertension 1986; Suppl. I: I169-73
36. Burrell LM, Phillips PA, Stephenson JM, et al. Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertension in the rat. Hypertension 1994; 23 (Pt 1): 737-43
37. Bursztyn M, Breshnahan M, Gavras I, et al. Pressor hormones in elderly hypertensive persons. Racial Differ Hypertens 1990; 15: 188-92
38. Bakris G, Bursztyn M, Gavras I, et al. Role of vasopressin in essential hypertension: racial differences. J Hypertens 1997; 15: 545-50
39. Torres VE. Vasopressin antagonists in polycystic kidney disease. Kidney Int 2005; 68: 2405-18
40. Gattone VH, Wang X, Harris PC, et al. Inhibition of renal cystic disease development and progression by vasopressin V2 receptor antagonist. Nat Med 2003; 9: 1323-6
41. Yamamura Y, Ogawa H, Yamashita H, et al. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol 1992; 105: 787-91
42. Lee CR, Watkins ML, Patterson JH, et al. Vasopressin: a new target for the treatment of heart failure. Am Heart J 2003; 146: 9-18l
43. Clair MJ, King MK, Goldberg A, et al. Selective vasopressin, angiotensin II, or dual receptor blockade with developing congestive heart failure. J Pharmacol Exp Ther 2000; 293: 852-60
44. Share L. Interrelations between vasopressin and the rennin-angiotensin system. Fed Proc 1979; 38: 2267-71
45. Cowley AW Jr, Lieard JF. Vasopressin and arterial pressure regulation. Hypertension 1988; 11: I25-32
46. Tabrizchi R, King K, Pang C. Vascular role of vasopressin in the presence and absence of influence from angiotensin II or alpha adrenergic system. Can J Physiol Pharmacol 1986; 64: 1143-8
47. Gavras H, Ribeiro AB, Kohlmann O, et al. Effects of a specific inhibitor of the vascular action of vasopressin in humans. Hypertension 1984; 6 Suppl. II: 56-60
48. Burrell LM, Phillips PA, Rolls KA, et al. Vascular responses to vasopressin antagonists in man and rat. Clin Sci 1994; 87: 389-95
49. Hirano T, Yamamura Y, Nakamura S, et al. Effects of the V2-receptor and antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther 2000; 292: 288-94
50. Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003; 107: 2690-6
51. Gheorghiade M, Gattis WA, O'Connor CM, et al., on behalf of the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive HF (ACTIV in CHF) Investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening HF: a randomized controlled trial. JAMA 2004; 291 (16): 1963-71
52. Udelson JE, Orlandi C, O'Brien T, et al. Vasopressin receptor blockade in patients with congestive heart failure: results from a placebo-controlled, randomized study comparing the effects of tolvaptan, furosemide, and their combination [abstract]. J Am Coll Cardiol 2002; 39: 156A
53. Udelson JE, the METEOR Trial Investigators. Multicenter, randomized double-blind, placebo-controlled, efficacy study on the effects of oral tolvaptan on LV dilatation and function in patients with HF and LV systolic dysfunction. The 9th Annual Scientific Meeting of Heart Failure Society of America; 2005 Sep 18-21; Boca Raton (FL)
54. Gheorghiade M, Orlanid C, Burnett J, et al., on behalf of the EVERST Study Investigators. Rationale and design of the multicenter, randomized double-blind, placebo-controlled study to evaluate the efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). J Card Fail 2005; 11: 260-9
55. Thibonnier M. Vasopressin receptor antagonists in heart failure. Curr Opin Pharmacol 2003; 3: 683-7
56. Abraham WT, Shamshiraz AA, McFann K, et al. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antaonist, in New York Heart Association Functional Class II and III chronic heart failure patients. J Am Coll Cardiol 2006; 47: 1615-21
57. Wong F, Blei AT, Blendis LM, et al. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, plavebo-controlled trial. Hepatology 2003; 37: 182-91
58. Gerbes AL, Gulberg V, Gines P, et al., on behalf of the VPA Study Group. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003; 124: 933-9
59. Soupart A, Gross P, Legros JJ, et al. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with SR 121 463 B, an orally active, nonpeptide, vasopressin V-2 receptor antagonist [abstract no. SU-PO140]. J Am Soc Nephrol 2004; 15: 563A
60. Yatsu T, Tomura Y, Tahara A, et al. Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V1a and V2 receptor antagonist, in dogs. Eur J Pharmacol 1997; 321: 225-30
61. Tahara A, Tomura Y, Wada K, et al. Pharmacological profile of YM087, a novel potent vasopressin V1a and V2 receptor antagonist, in vitro and in vivo. J Pharmacol Exp Ther 1997; 282: 301-8
62. Yatsu T, Tomura Y, Tahara A, et al. Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1a and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure. Eur J Pharmacol 1999; 376: 239-46
63. Verbalis JG, Bisaha JG, Smith N. Novel vasopressin V-1A and V2 antagonist (conivaptan) increases serum sodium concentration and effective water clearance in patients with hyponatremia. Circulation 2004; 110 (17I): 723
64. Ghali J, Koren MJ, Taylor JR, et al., on behalf of the Conivaptan Study Group. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic of hypervolemic hyponatremia. J Clin Endocrinol Metab 2006; 91: 2145-52
65. Russell S, Selaru P, Pyne DA, et al. Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin Antagonist in CHF patients undergoing Exercise) trial. Am Heart J 2003; 145: 179-86
66. Udelson JE, Smith WB, Hendrix GH, et al. Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001; 104: 2417-23
67. Ghali JK, Verbalis JG, Gross P, et al. Conivaptan, a novel arginine vasopressin antagonist, increased serum sodium concentration in patients with heart failure and euvolemic or hypervolemic hyponatremia [abstract]. J Am Coll Cardiol 2006; 47: 62A